Trial Profile

A phase 1 study of TERN-701 for chronic myeloid leukemia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TRN-000632 (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions

Most Recent Events

11 Aug 2023 New trial record
08 Aug 2023 According to a Terns Pharmaceuticals media release, expects to initiate a clinical trial for TERN-701 in the second half of 2023, with potential interim top-line readouts from initial dose-escalation cohorts in 2024.
08 Aug 2023 According to a Terns Pharmaceuticals media release, company s has completed drug manufacturing to enable the initiation of its Phase 1 trial for TERN-701.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com